Arca
Skip to content
Tools
Tools

CACNA1B: Voltage-dependent N-type calcium channel subunit alpha-1B

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death.

  • Drugs that act on it: 7
  • Approved: 3
  • In phases 1 to 3: 4
  • Sponsors: 5

Who Is On It, and How Far Along

Every drug ChEMBL records acting on CACNA1B, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule
  • Protein or peptide

Approved3

  • Levetiracetam
  • Ziconotide
  • Ziconotide acetate

Phase 31

  • Ralfinamide

Phase 23

  • Z160
  • CNV2197944
  • Elpetrigine

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Convergence Pharmaceuticals114%
    • Newron Pharmaceuticals SPA114%
    • Zalicus114%

    Modalities

    Drugs on this target by ChEMBL molecule type.

    • Small molecule571%
    • Protein or peptide229%

    The Landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Voltage-gated N-type calcium channel alpha-1B subunit blocker.
    LevetiracetamApprovedUCBSmall moleculeBlocker—41—
    ZiconotideApprovedEsteveProtein or peptideBlocker—4—
    Ziconotide acetateApprovedEsteveProtein or peptideBlocker—0—
    RalfinamidePhase 3Newron Pharmaceuticals SPASmall moleculeBlocker—0—
    Z160Phase 2ZalicusSmall moleculeBlocker—1—
    CNV2197944Phase 2Convergence PharmaceuticalsSmall moleculeBlocker—0—
    ElpetriginePhase 2—Small moleculeBlocker—0—

    Open Trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 13 in all, from ClinicalTrials.gov.
    Pharmacokinetics and Optimal Dosing of Levetiracetam in Critically Ill Patients Undergoing Continuous Renal Replacement TherapyLevetiracetam—RecruitingChulalongkorn University2026-11-05
    Levetiracetam as an Adjuvant Therapy to Hypothermia in Neonatal AsphyxiaLevetiracetamNot applicableNot yet recruitingAlexandria University2026-10-27
    Metabolically Fit CD19 CAR T Cells With CD34 Selection Markers in Adults With CD19-Positive B-Cell Acute Lymphocytic LeukemiaLevetiracetamPhase 1Not yet recruitingMedical University of South Carolina2026-10-26
    Levetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype GlioblastomaLevetiracetamPhase 2Not yet recruitingTianjin Medical University General Hospital2026-08-11
    Evaluating the Effectiveness of AIT in the Treatment of Pain Related to Pancreatic CancerZiconotideNot applicableNot yet recruitingClinique Bizet2026-07-29
    Intrathecal Ziconotide in Chemotherapy Induced Peripheral NeuropathyZiconotide—Not yet recruitingChristian Hospital Northeast Northwest2026-03-30
    Levetiracetam Three Times Daily in EpilepsyLevetiracetamPhase 3RecruitingWaad Alkathiri2026-03-24
    Levetiracetam for Persons at Risk for Alzheimer's DiseaseLevetiracetamPhase 2RecruitingSunnybrook Health Sciences Centre2026-03-17
    Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular LymphomaZ160Phase 2RecruitingThe First Affiliated Hospital with Nanjing Medical University2026-02-18
    Efficacy of Prophylactic Levetiracetam for Improving Functional Outcome in the Acute Phase of Intracerebral Haemorrhage: a Randomised, Double-blind, Placebo-controlled, Phase 3 TrialLevetiracetamPhase 3Not yet recruitingHospices Civils de Lyon2026-01-13
    Treatment of Seizures in Neonate With HIELevetiracetamPhase 4Not yet recruitingMansoura University2025-12-16
    Ziconotide for Non-cancer Pain by Intrathecal AdministrationZiconotide—RecruitingESTEVE Pharmaceuticals SAS2024-08-07
    OP2C : Prialt® Observatory in Clinical PracticeZiconotide—RecruitingInstitut Cancerologie de l'Ouest2020-03-25

    Diseases Most Associated With It

    Open Targets association score, 0 to 1; all associations
    Seizure
    0.72
    Neurodevelopmental disorder with seizures and non-epileptic hyperkinetic movements
    0.70
    Bilateral tonic-clonic seizure
    0.60
    Pain
    0.56
    Movement disorder
    0.53

    Genes and Related Targets

    Complexes and families that share a gene with this target
    Genes
    CACNA1B

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4478, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q00975, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.